Video

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Hussein A. Tawbi, MD, PhD, deputy chair, professor, director of melanoma clinical research and early drug development, director of personalized cancer therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdivo) in advanced melanoma.

The primary results of the ongoing, phase 3 RELATIVITY-047 trial (NCT03470922), which were presented during the 2021 ASCO Annual Meeting, demonstrated a more than doubled progression-free survival with the fixed-dose, first-line combination of relatlimab plus nivolumab vs nivolumab alone in patients with advanced melanoma.

Regarding safety, grade 3 or 4 treatment-related adverse effects (TRAEs) were observed in 18.9% of patients who received the combination vs 9.7% of patients who received the single agent, suggesting that the addition of relatlimab to nivolumab does not elicit significantly more toxicity compared with nivolumab alone, says Tawbi. As such, this regimen could offer patients with advanced melanoma a highly efficacious regimen without unacceptable toxicity, concludes Tawbi.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity